Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances

Vinge has advised Vicore Pharma Holding AB (publ) in connection with directed share issuances, whereby Vicore Pharma receives gross proceeds of SEK 500 million.

The share issuances were directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. One of the issuances is conditional upon approval by an extraordinary general meeting and that a prospectus is published. Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).

Vinge’s team has consisted of Rikard Lindahl, Joel Magnusson and Annie Fällström.

Related

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026

Vinge advises Zengun in connection with its issuance of bonds in an amount of SEK 750 million and its early redemption of outstanding bonds

Vinge has advised Zengun Group AB (publ) in connection with its issuance of senior secured bonds in an amount of SEK 750 million (within a framework of SEK 1,500 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
February 20, 2026

Vinge has advised Sluta Gräva in connection with its acquisition of Stavrex

Vinge has advised Sluta Gräv, a portfolio company of Sobro, in connection with the acquisition of Stavrex. Together, the companies form the Nordic region’s leading supplier of ground screws, with the market’s broadest offering.
February 18, 2026